Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
After a batch of new generics were approved in August towards December listing, Jiho has learned that copies of the SGLT2 inhibitor Forxiga (dapagliflozin propylene glycolate hydrate) developed by Sawai Pharmaceutical and T’s Pharma were cleared by circumventing remaining substance…
To read the full story
Related Article
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Draws 10 Generic Entrants in December Listing; Forxiga Has Two, but Nipro AG Absent
December 4, 2025
- Nipro Secures AG for Forxiga, Sawai and Teva Takeda Go Without Hydrate
August 18, 2025
- Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…